CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
| Revenue (TTM) | $462.25M |
| Gross Profit (TTM) | $417.00M |
| EBITDA | $262.55M |
| Operating Margin | 42.10% |
| Return on Equity | 54.90% |
| Return on Assets | 24.60% |
| Revenue/Share (TTM) | $5.91 |
| Book Value | $5.93 |
| Price-to-Book | 0.89 |
| Price-to-Sales (TTM) | 0.90 |
| EV/Revenue | 0.648 |
| EV/EBITDA | 1.16 |
| Quarterly Earnings Growth (YoY) | 6.70% |
| Quarterly Revenue Growth (YoY) | 156.50% |
| Shares Outstanding | $77.94M |
| Float | $65.89M |
| % Insiders | 7.61% |
| % Institutions | 57.65% |
Volatility is currently expanding
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call at 8:30 a.m. Eastern Standard Time.
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company's complete quarterly financial performance.
PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO® (rezafungin for injection) for the prophylaxis of invasive fungal disease. The sNDA was submitted by Mundipharma, CorMedix's global development partner, and the FDA has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date in Q1 2027. The sNDA is supported by the Phase III ReSPECT pivotal study, for which CorMedix announced positive topline results in April. ReSPECT evaluated the efficacy and safety of once weekly rezafungin (rezafungin acetate) compared with a standard antimicrobial regimen (SAR) for the prophylaxis of invasive fungal diseases in adults undergoing allogeneic HSCT. If REZZAYO is approved for this new indication, CorMedix is targeting to begin promotional efforts beginning in H2 2027.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better bang for their buck right now?
The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8 – 10, 2026.
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRMD and any ticker you trade — then tracks every position and per-strategy win rate.
